Autoantibodies to thyroglobulin in the blood
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
The reference values (norm) of the concentration of autoantibodies to thyroglobulin in serum are 0-51 IU / ml.
Autoantibodies to thyroglobulin in serum - antibodies to the predecessor of thyroid hormones. They bind thyroglobulin, disrupting the synthesis of hormones and thereby causing hypothyroidism.
Determination of antibodies to thyroglobulin is carried out to assess the severity of autoimmune reactions in thyroid diseases. The increase in their content reveals in most cases the thyroiditis of Hashimoto, Graves' disease and idiopathic myxedema. In the evaluation of the results of the study, the so-called "borderline" line, which is 70 IU / ml, is important and is used to differentiate patients with euthyroid status and patients with Hashimoto's thyroiditis and Graves disease. In patients with thyroiditis Hashimoto and Graves' disease, the antibodies to thyroglobulin more than 70 IU / ml are detected in 85 and 62% of patients, respectively. Specificity of this border for these diseases is 97%. In 55-85% of patients with autoimmune thyroiditis, the concentration of antibodies to thyroglobulin in the blood increases to 600 IU / ml and more. The absence of antibodies to thyroglobulin in patients with autoimmune thyroiditis is due either to the presence of thyroglobulin-antibody complexes in the blood, which do not react with thyroglobulin, or the formation of antibodies to another antigen.
Antibodies to thyroglobulin are detected in patients with thyroid cancer (in 45% of cases) in the presence of regional metastases, pernicious anemia (in 50%), systemic lupus erythematosus (in 20% of cases).
[